Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Diabetes Care. 2006;29(2):435-449.

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.